Skip to content

US · SPTX · BIOTECHNOLOGY

Seaport Therapeutics, Inc. Common Stock (SPTX) intrinsic value and stock valuation

$18.05as of 2026-11-21 · Mkt cap 1.2B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Seaport Therapeutics, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values SPTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SPTX’s statements →

Seaport Therapeutics, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02210-2186 seaporttx.com

How the business is doing

Fiscal 2025–2025, USD

Revenue
$0.00
20252025
Net income
-$-74.88M
20252025
Free cash flow
-$-78.3M
20252025
Total equity
-$-92.55M
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2025, USD
2025
Revenue$0.00
Operating income-$-87.29M
Net income-$-74.88M
EPSd-$-1.94M
Operating cash flow-$-77.94M
Capital expenditure-$-360K
Free cash flow-$-78.3M
Total assets$249M
Total debt$5.08M
Net debt-$-40.96M
Total equity-$-92.55M
Cash and short-term investments$216M
Income statement
2025
Revenue$0.00
Cost of revenue$0.00
Gross profit$0.00
Research and development expenses$66.3M
Selling, general and administrative expenses$21M
Other expenses$0.00
Operating expenses$87.3M
Cost and expenses$87.3M
Interest income$11.4M
Interest expense$0.00
Depreciation and amortization$1.41M
Ebitda-$-85.89M
Operating income-$-87.29M
Total other income/expenses, net$13.2M
Income before tax-$-74.11M
Income tax expense$770K
Net income-$-74.88M
Weighted average shares outstanding$38.7M
Weighted average diluted shares outstanding$38.7M
Balance sheet
2025
Cash and short-term investments$216M
Net receivables$3.03M
Inventory$0.00
Total current assets$223.2M
Property, plant and equipment, net$5.22M
Goodwill and intangible assets$0.00
Long-term investments$17.7M
Total non-current assets$25.8M
Total assets$249M
Accounts payable$2.01M
Short-term debt$1.64M
Deferred revenue$0.00
Total current liabilities$12.8M
Long-term debt$3.44M
Deferred revenue, non-current$0.00
Total non-current liabilities$328.8M
Capital lease obligations$5.08M
Total liabilities$341.6M
Common stock$0.00
Retained earnings-$-114.11M
Accumulated other comprehensive income (loss)$300K
Total equity-$-92.55M
Total investments$187.6M
Total debt$5.08M
Net debt-$-40.96M
Cash flow statement
2025
Net income-$-74.88M
Depreciation and amortization$1.41M
Stock-based compensation$6.88M
Change in working capital-$-7.93M
Accounts receivable$0.00
Inventory$0.00
Accounts payable-$-2.73M
Net cash provided by operating activities-$-77.94M
Investments in property, plant and equipment-$-360K
Acquisitions, net$0.00
Net cash used for investing activities-$-184.25M
Common stock issued$0.00
Common stock repurchased$0.00
Dividends paid$0.00
Net cash used for financing activities-$-870K
Net change in cash-$-263.06M
Cash at end of period$46.5M
Operating cash flow-$-77.94M
Capital expenditure-$-360K
Free cash flow-$-78.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Seaport Therapeutics, Inc. Common Stock

        Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.

        CEO
        Daphne Zohar
        Employees
        54
        Beta
        1.13

        Explore

        Frequently asked questions

        What is the intrinsic value of Seaport Therapeutics, Inc. Common Stock (SPTX)?

        InvestorsCraft does not currently publish an intrinsic value for SPTX. How the IC value is calculated.

        Is SPTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for SPTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.